SCHEMBL140212

SCHEMBL140212

CCC(CC)C(C(=O)O)(C(=O)O)c1ccc(N)c(F)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 1/20 0.37
HDAC1 Q13547 3/20 0.36
HDAC6 Q9UBN7 1/20 0.36
ALDH1A1 P00352 2/20 0.34
KCNN4 O15554 1/20 0.34
APP P05067 1/20 0.34
AKR1C3 P42330 3/20 0.33
AKR1C2 P52895 3/20 0.33
KIF11 P52732 1/20 0.33
KDM4E B2RXH2 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
MEN1 O00255 1/20 0.33
CYP1A2 P05177 1/20 0.33
KMT2A Q03164 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA4 P22748 1/20 0.33
CA6 P23280 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL142932 0.78 ATM (0.43) ALDH1A1HPGDMEN1KMT2A
SCHEMBL3711502 0.74 HDAC1 (0.42) HDAC1HDAC6ALDH1A1KCNN4APP
SCHEMBL24195985 0.74 APP (0.56) HDAC1HDAC6ALDH1A1KCNN4APP
SCHEMBL5001636 0.72 KCNN4 (0.42) HDAC1HDAC6KCNN4KIF11MEN1
SCHEMBL18936894 0.68 CYP3A4 (0.40) HDAC1HDAC6KIF11KEAP1HDAC3
SCHEMBL1590117 0.68 AKR1C3 (0.59) AKR1C3AKR1C2
SCHEMBL14035562 0.68 CNR2 (0.45) HDAC1HDAC6ALDH1A1APPAKR1C3
SCHEMBL30853648 0.68 TSHR (0.36) HDAC1HDAC6ALDH1A1KDM4EHSD17B10
SCHEMBL30192734 0.68 CNR2 (0.45) HDAC1HDAC6ALDH1A1APPAKR1C3
SCHEMBL5676081 0.68 HDAC1 (0.40) HDAC1HDAC6ALDH1A1APPAKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 US disclosed
EP-2408769-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS Glaxo Group Limited (GB) 2012-01-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS DTYMK, ITK, DCK PDE2A 2592/4885HDAC1 2724/4885HDAC6 2448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.